|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current assets | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Marketable securities | ||||||||||||||||||||
| Accounts receivable | ||||||||||||||||||||
| Inventories, net | ||||||||||||||||||||
| Other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Property, plant and equipment, net | ||||||||||||||||||||
| Operating lease right-of-use asset | ||||||||||||||||||||
| Intangible assets, net | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| TOTAL ASSETS | ||||||||||||||||||||
| Current liabilities | ||||||||||||||||||||
| Accounts payable and accrued liabilities | ||||||||||||||||||||
| Accrued compensation | ||||||||||||||||||||
| Current portion of operating lease liability | ||||||||||||||||||||
| Current portion of finance lease liability | ||||||||||||||||||||
| Deferred consideration from Rendiatech acquisition, current | ||||||||||||||||||||
| Other current liabilities | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Deferred consideration from Rendiatech acquisition, non-current | ||||||||||||||||||||
| Warrant liabilities | ||||||||||||||||||||
| Operating lease liability | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Mezzanine Equity | ||||||||||||||||||||
| Series J Convertible Preferred Stock as of June 30, 2026 and December 31, 2025, par value $0.0001 per share; authorized 600,000 shares, issued and outstanding 159 and 137, respectively | ||||||||||||||||||||
| Stockholders’ equity (deficit) | ||||||||||||||||||||
| Preferred stock | ||||||||||||||||||||
| Series A Junior Participating Preferred Stock | ||||||||||||||||||||
| Series F Convertible Preferred Stock | ||||||||||||||||||||
| Series I Convertible Preferred Stock | ||||||||||||||||||||
| Series F-1 Convertible Preferred Stock | ||||||||||||||||||||
| Total preferred stock | ||||||||||||||||||||
| Common stock as of June 30, 2026 and December 31, 2025, par value $0.0001 per share; authorized 100,000,000 shares, issued and outstanding 574,455 and 48,178, respectively | ||||||||||||||||||||
| Additional paid‑in capital | ||||||||||||||||||||
| Accumulated other comprehensive income: | ||||||||||||||||||||
| Foreign currency translation adjustment | ||||||||||||||||||||
| Unrealized gain (loss) on marketable securities | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total stockholders’ equity (deficit) | ||||||||||||||||||||
| TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT) | ||||||||||||||||||||
Loading...
